Low-dose Radiation Therapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19). Final results of a prospective phase I–II trial

Simple item page
dc.contributor.authorSanmamed, Noelia
dc.contributor.authorAlcántara Carrió, María Del Pino
dc.contributor.authorBustos García De Castro, Ana María
dc.contributor.authorCorona Sánchez, Juan Antonio
dc.contributor.authorGaztañaga Boronat, Miren
dc.contributor.authorCabello Clotet, Noemí
dc.contributor.authorOrtuño Andériz, Francisco
dc.contributor.authorCastro Fernández, Javier De
dc.contributor.authorFuentes Ramos, Manuel
dc.contributor.authorVazquez, Manuel
dc.contributor.editorMichael Baumann, MD
dc.date.accessioned2024-02-08T11:21:23Z
dc.date.available2024-02-08T11:21:23Z
dc.date.issued2022-03-30
dc.descriptionHighlights • LD-RT is feasible and well tolerated treatment for patients diagnosed with COVID-19. One week after LD-RT, 42% of the patients experienced a radiological response. • Thirty-nine percent of the patients experienced a rapid respiratory improvement (<72 h). • One week after LD-RT, 42% of the patients experienced a radiological response. • Patients were discharged a median of 11 days after LD-RT.
dc.description.abstractBackground and purpose: To evaluate the results of low-dose radiation therapy (LD-RT) to lungs in the management of patients with COVID-19 pneumonia. Material and methods: We conducted a prospective phase I-II trial enrolling COVID-19 patients ≥50 years-old, with bilateral lung involvement at imaging study and oxygen requirement (oxygen saturation ≤93% on room air). Patients received 1 Gy to whole lungs in a single fraction. Primary outcome was a radiological response assessed as severity and extension scores at days +3 and +7. Secondary outcomes were toxicity (CTCAE v5.0), days of hospitalization, changes in inflammatory blood parameters (ferritin, lymphocytes, C-reactive protein, d-dimer and LDH) and SatO2/FiO2 index (SAFI), at day +3 and +7. Descriptive analyses were summarized as means with standard deviation (SD) and/or medians with interquartile ranges (IQR). A Wilcoxon sign rank test for paired data was used to assess the CT scores and Chi Square was used to assess for comparison of categorical variables. Results: Forty-one patients were included. Median age was 71 (IQR 60-84). Eighteen patients (44%) previously received an anti-COVID treatment (tocilizumab, lopinavir/ritonavir, remdesivir) and thirty-two patients (84%) received steroids during LD-RT. The extension score improved significantly (p = 0.02) on day +7. Mean baseline extension score was 13.7 (SD ± 4.9) with a score of 12.2 (±5.2) at day 3, and 12.4 ± 4.7 at day 7. No differences were found in the severity score. SAFI improved significantly on day +3 and +7 (p < 0.01). Median SAFI on day 0 was 147 (IQR 118-264), 230 (IQR 120-343) on day +3 and 293 (IQR 121-353) on day +7. Significant decrease was found in C-reactive protein on day +7 (p = 0.02) and in lymphocytes counts on day +3 and +7 (p = 0.02). The median number of days in hospital after RT was 11 (range 4-78). With a median follow-up of 60 days after LD-RT, 26 (63%) patients were discharged, 11 (27%) died because of COVID respiratory failure and 4 (10%) died of other causes. Conclusions: LD-RT is a feasible and well-tolerated treatment that could lead to rapid clinical improvement. Large randomized trials would be required to establish the efficacy of LD-RT to treat COVID-19 pneumonia.
dc.description.departmentDepto. de Radiología, Rehabilitación y Fisioterapia
dc.description.facultyFac. de Medicina
dc.description.facultyUniversidad Complutense de Madrid
dc.description.refereedTRUE
dc.description.statuspub
dc.identifier.citationSanmamed N, Alcantara P, Gómez S, Bustos A, Cerezo E, Gaztañaga M, Doval A, Corona J, Rodriguez G, Cabello N, Duffort M, Ortuño F, de Castro J, López A, Fuentes M, Sanz A, Vazquez M. Low-dose Radiation Therapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19). Final results of a prospective phase I-II trial. Radiother Oncol. 2022 Jun;171:25-29. doi: 10.1016/j.radonc.2022.03.015. Epub 2022 Mar 31. PMID: 35367528; PMCID: PMC8968128.
dc.identifier.doi10.1016/j.radonc.2022.03.015
dc.identifier.issn0167-8140
dc.identifier.officialurlhttp://dx.doi.org/10.1016/j.radonc.2022.03.015
dc.identifier.relatedurlhttps://pubmed.ncbi.nlm.nih.gov/35367528/
dc.identifier.urihttps://hdl.handle.net/20.500.14352/100338
dc.issue.number171
dc.journal.titleRadiotherapy and Oncology
dc.language.isoeng
dc.page.final29
dc.page.initial25
dc.publisherElsevier
dc.relation.projectIDTrial Low-Dose Radiation Therapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19)
dc.rights.accessRightsrestricted access
dc.subject.cdu615.849.1
dc.subject.keywordBenign disease
dc.subject.keywordCOVID-19
dc.subject.keywordLD-RT
dc.subject.keywordPneumonia
dc.subject.keywordRadiation
dc.subject.ucmCiencias Biomédicas
dc.subject.unesco32 Ciencias Médicas
dc.titleLow-dose Radiation Therapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19). Final results of a prospective phase I–II trial
dc.typejournal article
dc.type.hasVersionAM
dc.volume.number2022
dspace.entity.typePublication
relation.isAuthorOfPublicationd57a2409-23f5-41af-b8b9-680c861e9502
relation.isAuthorOfPublicationbe5af101-c734-49a5-87dc-8396a4907a99
relation.isAuthorOfPublication710a1eb1-0353-4931-98a3-86081b4467d3
relation.isAuthorOfPublicatione55c3b8b-7774-44dc-b0c1-b87e1b197ee1
relation.isAuthorOfPublicationac0d98c9-7d90-45f4-859e-09aad38abc58
relation.isAuthorOfPublicationc663af30-271f-47da-a521-7d5c16e943f0
relation.isAuthorOfPublicationeb2f75d1-bb29-4ff3-a44c-670139ea0b5a
relation.isAuthorOfPublication845df5dc-2a3e-4b82-9961-e163d28ed5f9
relation.isAuthorOfPublication.latestForDiscoverybe5af101-c734-49a5-87dc-8396a4907a99
Download
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Low-dose Radiation Therapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19). Final results of a prospective phase I–II trial 2022.pdf
Size:
345.26 KB
Format:
Adobe Portable Document Format
Download
Collections
Artículos